Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02693080 · ClinicalTrials.gov registry record · Phase 1
CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02693080: Completed Phase 1 study, sponsored by Stanford University.
NCT02693080 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02693080, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study assesses computed tomography (CT) perfusion imaging in predicting treatment response in patients with non-small cell lung cancer or tumors that have spread from the primary site (place where it started) to the lungs (metastases) treated with stereotactic ablative radiation therapy. CT perfusion imaging is a special type of CT that uses an injected dye in order to see how blood flow through tissues, including lung tissue. CT perfusion imaging of the lungs may help doctors learn whether perfusion characteristics of lung tumors may be predictive of response to treatment and whether lung perfusion characteristics can be used to follow response to treatment.
Interventions
- RADIATION Computed Tomography Perfusion Imaging
- DEVICE CAPP-Seq
- DRUG Isovue-200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-01-19 |
| Est. Completion | 2020-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02693080
The ClinicalTrials.gov registry entry for NCT02693080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Computed Tomography Perfusion Imaging is the first listed.
NCT02693080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02693080 about?
NCT02693080 is a clinical study titled "CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy". This study assesses computed tomography (CT) perfusion imaging in predicting treatment response in patients with non-small cell lung cancer or tumors that have spread from the primary site (place where it started) to the lungs (metastases) treated with stereotactic ablative radiation therapy. CT per...
What is the current status of trial NCT02693080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2016-01-19. Estimated completion is 2020-04-29.
What interventions are being tested in trial NCT02693080?
The interventions under investigation include: Computed Tomography Perfusion Imaging (RADIATION), CAPP-Seq (DEVICE), Isovue-200 (DRUG).
Who is sponsoring clinical trial NCT02693080?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.